1. Home
  2. VET vs DVAX Comparison

VET vs DVAX Comparison

Compare VET & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vermilion Energy Inc.

VET

Vermilion Energy Inc.

HOLD

Current Price

$8.26

Market Cap

1.3B

Sector

Energy

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$15.41

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VET
DVAX
Founded
1994
1996
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
VET
DVAX
Price
$8.26
$15.41
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$26.50
AVG Volume (30 Days)
1.5M
5.0M
Earning Date
11-05-2025
02-19-2026
Dividend Yield
4.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,445,514,003.00
$330,514,000.00
Revenue This Year
$11.40
$24.63
Revenue Next Year
N/A
$15.85
P/E Ratio
N/A
N/A
Revenue Growth
30.48
26.73
52 Week Low
$5.14
$9.20
52 Week High
$10.49
$15.49

Technical Indicators

Market Signals
Indicator
VET
DVAX
Relative Strength Index (RSI) 48.46 88.47
Support Level $7.76 $10.78
Resistance Level $8.64 $15.45
Average True Range (ATR) 0.25 0.10
MACD -0.01 0.15
Stochastic Oscillator 57.06 98.41

Price Performance

Historical Comparison
VET
DVAX

About VET Vermilion Energy Inc.

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: